An independent Data Monitoring Committee reviewed Bristol Myers Squibb’s CheckMate -548 Phase III trial of Opdivo (nivolumab) plus current standard of care in patients with newly diagnosed glioblastoma multiforme with 06-methylguanine-DNA methyltransferase promoter methylation following surgical resection of the tumor, and indicated the study would not meet the primary endpoint of overall survival.

MetVital’s lead drug candidate “Anhydrous Enol-Oxaloacetate” (AEO) received Fast Track Designation from the U.S. Food and Drug Administration for the treatment of patients with newly diagnosed glioblastoma multiforme.

Bristol-Myers Squibb’s Phase III CheckMate -548 study of Opdivo (nivoumab) added to current standard of care to treat brain cancer – newly diagnosed glioblastoma multiforme – did not meet one of the primary endpoints, progression-free survival. The clinical trial will continue to evaluate the other primary endpoint, overall survival.